MASP-2 inhibitors and methods of use

1. A compound having the following Structure (I):

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein:

R 1 is a substituted phenyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted heterocyclyl,

wherein the substituted phenyl of R 1 is selected from the group consisting of:

wherein the substituted or unsubstituted heteroaryl of R 1 is a 5-10 membered heteroaryl selected from the group consisting of:

wherein the substituted or unsubstituted cycloalkyl of R 1 is a C3-C6 cycloalkyl monocyclic or polycyclic ring system, which is saturated or unsaturated, and which can comprise fused or bridged ring systems, and the substituted cycloalkyl of R 1 is substituted with one or more of R 1a , R 1b , R 1c , R 1d , and R 1e , wherein R 1a , R 1b , R 1c , R 1d , and R 1e are each independently selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, aminylalkyl, hydroxyalkyl, nitro, OR 9 , SR 9 , C(O)R 9 , C(O)NR 9 R 10 , C(O)OR 9 , OC(O)R 9 , OC(O)OR 9 , OC(O)NR 9 R 10 , NR 9 R 10 , N(R 9 )C(O)R 10 , N(R 9 )C(O)NR 10 R 11 , N(R 9 )C(O)OR 10 , C(═NR)NR 10 R 11 , C(═NOR 9 )NR 10 R 11 , C(═NOC(O)R 9 )NR 10 R 11 , C(═NR 9 )N(R 10 )C(O)OR 11 , N(R 9 )C(═NR 10 )NR 11 R 12 , S(O)R 9 , S(O)NR 9 R 10 , S(O) 2 R 9 , N(R 9 )S(O) 2 R 10 , S(O) 2 NR 9 R 10 , oxo, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted C 6-10 arylalkyl, substituted or unsubstituted C 6-10 aryloxy, substituted or unsubstituted C 6-10 arylalkoxy, substituted or unsubstituted 5-10 membered heteroaryl, substituted or unsubstituted C 3-10 cycloalkyl, and substituted or unsubstituted 4-10 membered heterocyclyl,

wherein R 9 , R 10 , R 11 , and R 12 , are, at each occurrence, independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, hydroxyl, C 1-6 alkoxy, aryl, arylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, cycloalkyl, heterocyclyl, and heteroaryl,

wherein the R 1a , R 1b , R 1c , R 1d , or R 1e is optionally substituted with one or more substituents selected from the group consisting of OR 13 , SR 13 , C(O)R 13 , C(O)NR 13 R 14 , C(O)OR 13 , OC(O)R 13 , OC(O)NR 13 R 14 , NR 13 R 14 , NR 13 C(O)R 14 , NR 13 C(O)NR 14 R 15 , NR 13 C(O)OR 14 , C(═NR 13 )NR 14 R 15 , NR 13 C(═NR 14 )NR 15 R 16 , S(O)R 13 , S(O)NR 13 R 14 , S(O) 2 R 13 , NR 13 S(O) 2 R 14 , S(O) 2 NR 13 R 14 and oxo when R 1a , R 1b , R 1c , R 1d , or R 1e is a substituted C 6-10 aryl, a substituted C 6-10 arylalkyl, a substituted C 6-10 aryloxy, a substituted C 6-10 arylalkoxy, a substituted 5-10 membered heteroaryl, a substituted C 3-10 cycloalkyl, and a substituted 4-10 membered heterocyclyl,

wherein R 13 , R 14 , R 15 , and R 16 are, at each occurrence, independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, hydroxyl, C 1-6 alkoxy, aryl, arylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, cycloalkyl, heterocyclyl, and heteroaryl,

wherein the substituted or unsubstituted heterocyclyl of R 1 is a 4-10 membered monocyclic, bicyclic, tricyclic, or tetracyclic ring system consisting of carbon atoms and one to six heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and which can comprise fused, bridged, and spiro ring systems, and the substituted heterocyclyl of R 1 is substituted with one or more of R 1a , R 1b , R 1c , R 1d , and R 1e , wherein R 1a , R 1b , R 1c , R 1d , and R 1e are each independently selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, C 1-6 haloalkyl, aminylalkyl, hydroxyalkyl, cyano, nitro, OR 9 , SR 9 , C(O)R 9 , C(O)NR 9 R 10 , C(O)OR 9 , OC(O)R 9 , OC(O)OR 9 , OC(O)NR 9 R 10 , NR 9 R 10 , N(R 9 )C(O)R 10 , N(R 9 )C(O)NR 10 OR 11 , N(R 9 )C(O)OR 10 , C(═NR 9 )NR 10 R 11 , C(═NOR 9 )NR 10 R 11 , C(═NOC(O)R 9 )NR 10 R 11 , C(═NR 9 )N(R 10 )C(O)OR 11 , N(R 9 )C(═NR 10 )NR 11 R 12 , S(O)R 9 , S(O)NR 9 R 10 , S(O) 2 R 9 , N(R 9 )S(O) 2 R 10 , S(O) 2 NR 9 R 10 , oxo, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted C 6-10 arylalkyl, substituted or unsubstituted C 6-10 aryloxy, substituted or unsubstituted C 6-10 arylalkoxy, substituted or unsubstituted 5-10 membered heteroaryl, substituted or unsubstituted C 3-10 cycloalkyl, and substituted or unsubstituted 4-10 membered heterocyclyl,

wherein R 9 , R 10 , R 11 , and R 12 , are, at each occurrence, independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, hydroxyl, C 1-6 alkoxy, aryl, arylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, cycloalkyl, heterocyclyl, and heteroaryl, and

wherein the R 1a , R 1b , R 1c , R 1d , or R 1e is optionally substituted with one or more substituents selected from the group consisting of halo, CN, OR 13 , SR 13 , C(O)R 13 , C(O)NR 13 R 14 , C(O)OR 13 , OC(O)R 13 , OC(O)NR 13 R 14 , NR 13 R 14 , NR 13 C(O)R 14 , NR 13 C(O)NR 14 R 15 , NR 13 C(O)OR 14 , C(═NR 13 )NR 14 R 15 , NR 13 C(═NR 14 )NR 15 R 16 , S(O)R 13 , S(O)NR 13 R 14 , S(O) 2 R 13 , NR 13 S(O) 2 R 14 , S(O) 2 NR 13 R 14 and oxo when R 1a , R 1b , R 1c , R 1d , and R 1e is a substituted C 6-10 aryl, a substituted C 6-10 arylalkyl, a substituted C 6-10 aryloxy, a substituted C 6-10 arylalkoxy, a substituted 5-10 membered heteroaryl, a substituted C 3-10 cycloalkyl, and a substituted 4-10 membered heterocyclyl, and

wherein R 13 , R 14 , R 15 , and R 16 are, at each occurrence, independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, hydroxyl, C 1-6 alkoxy, aryl, arylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, cycloalkyl, heterocyclyl, and heteroaryl;

R 2a , R 2b , R 2c , and R 2d are each independently selected from the group consisting of hydrogen, halo, C(═O)OR 5 , OC(═O)R 5 , hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, cyano, aminylalkyl, carboxyalkyl, NR 5 R 6 , C(═O)NR 5 R 6 , N(R 5 )C(═O)R 6 , NR 5 C(═O)NR 6 , S(O) t , SR 5 , nitro, N(R 5 )C(O)OR 6 , C(═NR 5 )NR 6 R 7 , N(R 5 )C(═NR 6 )NR 7 R 8 , S(O)R 5 , S(O)NR 5 R 6 , S(O) 2R 5 , N(R 5 )S(O) 2 R 6 , S(O) 2 NR 5 R 6 , aryl, heteroaryl, heterocyclyl, cycloalkyl, and oxo, provided that at least one of R 2a , R 2b , R 2c , and R 2d is not hydrogen;

R 3 is NR 3a R 3b ;

R 3a and R 3b are each independently hydrogen, alkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, cycloalkyl, (CH 2 ) n C(═O)OR 6 , or (CH 2 ) n P(═O)(OR 6 ) 2 ; or R 3a and R 3b , together with the nitrogen to which they are attached, form a 5-7 membered heteroaryl or a 4-7 membered heterocyclyl; or R 3a and R 4 together with the nitrogen and carbon to which they are attached, respectively, form a 4-7 membered heterocyclyl, and R 3b is hydrogen, alkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, cycloalkyl, (CH 2 ) n C(═O)OR 6 , or (CH 2 ) n P(═O)(OR 6 ) 2 ;

R 4 is an aryl, a heteroaryl, a cycloalkyl, or a heterocyclyl when n is 2, 3, 4, 5, or 6;

or R 4 is a monocyclic heteroaryl, or a heterocyclyl when n is 0 or 1; or R 4 and R 3a together with the carbon and nitrogen to which they are attached, respectively, form a 4-7 membered heterocyclyl;

R 5 , R 6 , R 7 , and R 8 are, at each occurrence, independently hydrogen, alkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, carboxyalkyl, heterocyclyl, heteroaryl, or cycloalkyl;

n is an integer from 0-6; and

t is an integer from 1-3, and

wherein the aryl of R 2a , R 2b , R 2c , R 2d , R 4 is a 6- to 18-membered monocyclic, bicyclic, tricyclic, or tetracyclic ring system comprising at least one aromatic ring, and which can comprise fused or bridged ring systems,

wherein the heteroaryl of R 2a , R 2b , R 2c , R 2d , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 is a 5- to 14-membered monocyclic, bicyclic, tricyclic, or tetracyclic ring system comprising at least one aromatic ring and one to six heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and which can comprise fused or bridged ring systems,

wherein the heterocyclyl of R 2a , R 2b , R 2c , R 2d , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , and R 8 is a 3- to 18-membered monocyclic, bicyclic, tricyclic, or tetracyclic ring system consisting of two to twelve carbon atoms and one to six heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and which can comprise fused, bridged, and spiro ring systems, and

wherein the cycloalkyl of R 2a , R 2b , R 2c , R 2d , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , and R 8 is a 3- to 15-membered monocyclic or polycyclic ring system, which is saturated or unsaturated, and which can comprise fused or bridged ring systems.

2. The compound of claim 1 , wherein R 1 is a pyridinyl, pyrrolopyridinyl, or benzoimidazolyl.

3. The compound of claim 1 , wherein the compound has one of the following structures:

4. The compound of claim 1 , wherein at least one of R 2a , R 2b , R 2c , and R 2d is alkoxy, alkoxyalkyl, cyano, halo, C(═O)OR 5 , OC(═O)R 5 , C(═O)NR 5 R 6 , N(R 5 )C(═O)R 6 , aryl, heteroaryl, heterocyclyl, or C(═O)N(R 5 )heterocyclyl, wherein R 5 and R 6 are, at each occurrence, independently hydrogen or C 1 -C 6 alkyl.

5. The compound of claim 1 , wherein at least one of R 2a , R 2b , R 2c , and R 2d has one of the following structures:

6. The compound of claim 1 , wherein R 3 has one of the following structures:

7. The compound of claim 1 , wherein n is 0, 1, or 2.

8. The compound of claim 1 , wherein n is 2 and R 4 is an aryl.

9. The compound of claim 8 , wherein R 4 has one of the following structures:

10. The compound of claim 1 , wherein n is 2 and R 4 is a heteroaryl.

11. The compound of claim 10 , wherein R 4 has one of the following structures:

12. The compound of claim 1 , wherein R 4 has one of the following structures:

13. A compound of claim 1 , having one of the structures:

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.